Aphaia Pharma Announces Enrollment of First Patient in Phase 2 Study of APH-012 for Chronic Weight Management in Individuals with Obesity
ZUG, Switzerland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage biopharmaceutical company harnessing precision-targeted drug delivery technology for...